SAN DIEGO, DEC. 6 -- ZIOPHARM, Inc. today announced that Dr. Xiaodong Cheng, MD from The University of Texas M.D. Anderson Cancer Center presented preclinical data on ZIO-102, the second of the Company's organic arsenic products. Data were presented at the 46th Annual Meeting of the American Society of Hematology (ASH), December 3-8, in San Di...  

NEW HAVEN, CT. OCT. 26 - ZIOPHARM, Inc. announced it received a Notice of Allowance from the US Patent and Trademark Office for US Patent Application No. 10/337969 titled "S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(simethylarsino) glutathione as treatments for cancer."

The patent application claims both ...  

NEW HAVEN, CT SEPT 15 - Privately held ZIOPHARM, Inc., a developer of cancer drugs, announced it named eight individuals with diverse backgrounds in medicine, pharmaceutical and biotechnology management, legal and government affairs, and finance and communications to its board of directors under the leadership of Chief Executive Officer Jonatha...  

NEW HAVEN, CT SEPTEMBER 14 - Newly formed and privately held ZIOPHARM, Inc., headed by chief executive officer Jonathan J. Lewis, MD, PhD announced the members of its senior management team whose positions are effective immediately.

"This is a 'Dream Team' for a cancer products company," said Dr. Lewis, former chief medical officer of ...  

NEW YORK, NY MAY 5 - New cancer treatments could be developed faster and cheaper if outdated study strategies were replaced with more relevant science-based methods designed to facilitate faster decisions.

In today's invited lecture (May 6th-Melbourne, Australia time) to the 2004 Annual Scientific Congress of the Royal Australasian Col...